Phase II study of pegylated liposomal doxorubicin: Inactive in recurrent small-cell lung cancer: A hellenic cooperative oncology group study

Annals of Oncology

Volumn 11, Issue 11, 2000, Pages 1395-1397

  Samantas, E ^a   Kalofonos, H ^b   Linardou, H ^a   Nicolaides, C ^c   Mylonakis, N ^d   Fountzilas, G ^e   Kosmidis, P ^f   Skarlos, D ^a  

^a AGII ANARGIRI CANCER HOSPITAL   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

^d Anticancer Hospital   (Greece)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f HYGEIA HOSPITAL   (Greece)

Author keywords

Liposomal doxorubicin; Phase II; Recurrent small cell lung cancer

Indexed keywords

DOXORUBICIN; ETOPOSIDE; PLATINUM;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEMALE; HUMAN; KAPOSI SARCOMA; LUNG SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0033638112     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026523316736     Document Type: Article

References (12)

1. Treatment of relapsed small-cell lung cancer
2. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British Medical Research Council Multicenter Randomised Trial. Medical Research Council Lung Cancer Working Party
3. Randomised study of cyclophosphamide, doxorubicin, and vincristine vs. etoposide and cisplatin vs. alterations of these two regimens in extensive stage SCLC: A phase III trial of the Southeastern Cancer Study Group
4. Cyclophosphamide, doxorubicin and vincristine in etoposide- and cisplatin-resistant small-cell lung cancer
5. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
6. Randomised comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma
7. Treatment of advanced breast cancer with sterically stabilised liposomal doxorubicin: Results of a multicenter phase II trial
8. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer
9. Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small-cell lung cancer
10. A phase II study of Doxil (liposomal doxorubicin): Lack of activity in poor prognosis soft tissue sarcomas
11. Doxil in patients with pretreated metastatic breast cancer (MBC): A dose-schedule finding study with pharmacokinetics